Generation and testing of clinical-grade exosomes for pancreatic cancer
Top Cited Papers
Open Access
- 19 April 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (8)
Abstract
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.Keywords
Funding Information
- University of Texas MD Anderson Cancer Center (Pancreas Cancer Moonshot)
- Cancer Prevention and Research Institute of Texas (N/A)
- Instituto Nacional de Cancerología (NCI CA213233)
- Instituto Nacional de Cancerología (NCI P01 CA117969)
- Instituto Nacional de Cancerología (NCI CA195733)
- University of Texas MD Anderson Cancer Center (Khalifa Bin Zayed Al Nahya Foundation)
- Instituto Nacional de Cancerología (High Resolution Electron Microscopy Facility Institutional Core Grant CA16672)
- Instituto Nacional de Cancerología (NIH P30CA16672)
- Instituto Nacional de Cancerología (MDACC Small Animal Imaging Facility NIH P30-CA016672)
- Instituto Nacional de Cancerología (5U24-CA126577)
This publication has 34 references indexed in Scilit:
- Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical UseInternational Journal of Molecular Sciences, 2017
- A Good Manufacturing Practice–grade standard protocol for exclusively human mesenchymal stromal cell–derived extracellular vesiclesCytotherapy, 2017
- Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challengesActa Pharmaceutica Sinica B, 2016
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancerNature, 2015
- Small RNA combination therapy for lung cancerProceedings of the National Academy of Sciences, 2014
- Extracellular vesicles: biology and emerging therapeutic opportunitiesNature Reviews Drug Discovery, 2013
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategiesCell Research, 2012
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sitesNucleic Acids Research, 2005
- Lack of interferon response in animals to naked siRNAsNature Biotechnology, 2004